NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Palvella Therapeutics, Inc. (PVLA) Stock Analysis

Palvella Therapeutics, Inc. (PVLA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PVLA

$157.24

+$1.77 (+1.14%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PVLA with… →

PVLA Key Statistics

As of Sep 4, 2026
Trading
Open
$152.95
Previous Close
$155.47
Day's Range
152.95–157.45
52-Week Range
52.82–161.38
Volume
162.30K
Valuation
Market Cap
$2.27B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.85
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$41.72M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.41M
1-Year Return
+190.43%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
246.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PVLA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+50.22%
2025+772.25%
2024−17.58%
2023−82.50%
2022−72.49%
2021+51.20%
2020−30.94%
2019+36.09%
2018−64.77%
2017+437.37%
2016 (partial year)−15.36%

As of September 4, 2026.

PVLA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$41.72M—
2024$0.00−$17.43M—
2023$0.00$18.69M—
2022$0.00−$27.55M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$38.60M−$41.72M—
2024$0.00—−$14.10M−$17.43M—
2023$0.00—−$11.87M$18.69M—
2022$0.00—−$18.04M−$27.55M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PVLA Valuation vs Biotechnology Median

Median of 656 stocks
MetricPVLABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Palvella Therapeutics, Inc. (PVLA) at $2.27B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 29.

Over the past 52 weeks the price has ranged from $52.82 to $161.38. The most recent close on file for PVLA is $157.24, dated September 4, 2026. That is +$1.77 (+1.14%) against the previous close. The latest close sits 197.69% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $41.72M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −4.85.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Daily returns over the trailing 10 years annualize to a volatility of 91.74%. Over the trailing twelve months the price has returned +190.43%. Across 10 years the annualized return works out at +2.02%.

Growth & Income

The record shows no dividend for PVLA.

The strongest complete calendar year on file is 2025 at +772.25%; the weakest is 2023 at −82.50%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is +50.22%.

Peer Comparison

Palvella Therapeutics, Inc. (PVLA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Palvella Therapeutics, Inc. PVLA $2.27B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Palvella Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.

Visit website →